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The affinity of integrin IIb3 for fibrinogen is con-
trolled by inside-out signals that are triggered by ago-
nists like thrombin. Agonist treatment of platelets also
activates Rap1b, a small GTPase known to promote in-
tegrin-dependent adhesion of other cells. Therefore, we
investigated the role of Rap1b in IIb3 function by viral
transduction of GFP-Rap1 chimeras into murine
megakaryocytes, which exhibit inside-out signaling sim-
ilar to platelets. Expression of constitutively active
GFP-Rap1b (V12) had no effect on unstimulated
megakaryocytes, but it greatly augmented fibrinogen
binding to IIb3 induced by a PAR4 thrombin receptor
agonist (p < 0.01). The Rap1b effect was cell-autonomous
and was prevented by pre-treating cells with cytochala-
sin D or latrunculin A to inhibit actin polymerization.
Rap1b-dependent fibrinogen binding to megakaryo-
cytes was blocked by POW-2, a novel monovalent anti-
body Fab fragment specific for high affinity murine
IIb3. In contrast to GFP-Rap1b (V12), expression of
GFP-Rap1GAP, which deactivates endogenous Rap1, in-
hibited agonist-induced fibrinogen binding (p < 0.01), as
did dominant-negative GFP-Rap1b (N17) (p < 0.05).
None of these treatments affected surface expression of
IIb3. These studies establish that Rap1b can augment
agonist-induced ligand binding to IIb3 through effects
on integrin affinity, possibly by modulating IIb3 inter-
actions with the actin cytoskeleton.
The IIb3 integrin is a receptor for adhesive ligands such as
fibrinogen and von Willebrand factor, and ligand binding to
IIb3 is required for platelet aggregation and spreading in
hemostasis. Ligand binding is regulated by positive and nega-
tive “inside-out” signals that converge on IIb3 to control the
integrin activation state through modulation of receptor affin-
ity or avidity (1). Affinity modulation, the dominant mode of
regulation in platelets, implies a change in the conformation of
the IIb3 heterodimer to increase access of ligand binding
sites, while avidity modulation implies lateral movements of
heterodimers in the plane of the plasma membrane, culminat-
ing in integrin clustering (2–4). Positive inside-out signals can
be initiated by agonist occupancy of several different classes of
excitatory receptors that couple to heterotrimeric G proteins
and tyrosine kinases (5–10). IIb3 activation can be negatively
regulated by prostacyclin or nitric oxide, whose effects are
mediated through cyclic AMP and cyclic GMP, respectively (5).
The signaling molecules directly responsible for regulation of
IIb3 downstream of excitatory receptors are incompletely
characterized. Nonetheless, isoforms of protein kinase C and
PI1 3-kinase as well as cytoplasmic free Ca2 have been iden-
tified as key signaling intermediates (1, 5). In addition, IIb3
function in platelets appears to be regulated in some way by the
actin cytoskeleton because inhibition of actin polymerization by
low micromolar concentrations of cytochalasin D or latrunculin
A increases agonist-dependent fibrinogen binding, whereas
higher concentrations of these agents partially inhibit fibrino-
gen binding (11). Therefore, protein kinase C, PI 3-kinase, and
Ca2 may introduce post-translational modifications in signal-
ing/cytoskeletal proteins that associate with and regulate
IIb3 (1, 12). However, major gaps remain in the identification
and characterization of integrin regulatory proteins in
platelets.
The Ras family GTPase, Rap1b, may be one such integrin
regulatory protein. Like other Ras family members, it cycles
from an inactive, GDP-bound form to an active, GTP-bound
form, with cycling regulated by one or more guanine nucleotide
exchange factors (GEFs), guanine nucleotide dissociation in-
hibitors (GDIs), and GTPase-activating proteins (GAPs) (13).
Rap1b is highly expressed in platelets, is rapidly activated in
response to agonists such as thrombin, ADP, or epinephrine
and partitions along with IIb3 to the Triton-insoluble core
actin cytoskeleton of aggregated platelets (14–16). Rap1b acti-
vation in response to thrombin depends initially on Ca2 fluxes
into the platelet cytoplasm and subsequently on protein kinase
C (17). Although the function of Rap1b in platelets is unknown,
it has been implicated in promoting 1 and 2 integrin-depend-
ent adhesion of fibroblastic and hematopoietic cell lines and
murine thymocytes (18–22). The evidence for this is based
largely on overexpression of constitutively active and domi-
nant-negative forms of Rap1, but additional support for Rap1
involvement comes from studies of mouse embryonic fibro-
blasts deficient in the Rap1 GEF, C3G, which exhibit defective
integrin-dependent adhesion that is correctable by expression
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of a constitutively active Rap1 mutant (23). Because, cell ad-
hesion by integrins is dependent on a combination of factors,
including inside-out signaling, ligand binding, and post-ligand
binding events, the precise mechanism(s) whereby Rap1 pro-
motes adhesion may vary with the integrin and the cell type.
Based on these considerations, the present study was carried
out to determine whether Rap1b is an effector of inside-out
signaling to IIb3. Because platelets are not amenable to ge-
netic manipulation, we used Sindbis virus vectors to express
specific GFP-tagged chimeric proteins in primary, mature mu-
rine megakaryocytes. Megakaryocytes are nucleated cells that
function primarily to produce platelets, and like platelets they
exhibit an inside-out signaling pathway from excitatory recep-
tors to IIb3 (24–26). The results establish that Rap1b, in
concert with platelet agonists, can promote fibrinogen binding
to IIb3. Furthermore, they indicate that Rap1b functions to
modulate IIb3 affinity, possibly through effects on the actin
cytoskeleton.
EXPERIMENTAL PROCEDURES
Construction of Sindbis Virus Vectors—Enhanced green fluorescent
protein (GFP) was amplified by PCR using pEGFP-C1 as a template
(CLONTECH, Palo Alto, CA) and cloned into the MluI/SphI sites of the
Sindbis expression vector, pSinRep5 (Invitrogen, Carlsbad, CA). Full-
length human Rap1b (V12) or Rap1b (N17) cDNAs in pGBT9 and
pCGN, respectively, were PCR-amplified to generate XbaI/SphI frag-
ments and directionally cloned into pSinRep5. Then a XbaI/XbaI GFP
cassette was subcloned in-frame into this plasmid to create GFP-Rap1b
(V12) or GFP-Rap1b (N17) fusions. GFP-Rap1GAP in pSinRep5 was
generated by cloning PCR-amplified human Rap1GAP (a generous gift
from Alan Hall, London) as a MluI/MluI fragment, followed by a 5
in-frame insertion of the GFP cassette. Insert orientations were verified
by colony PCR, and all coding sequences were verified in the Sindbis
vectors by automated DNA sequencing.
To produce Sindbis viruses encoding mRNA for the GFP chimeras,
the pSinRep5 plasmids and a helper plasmid (DH26S) were linearized
and used as a template to synthesize in vitro capped and polyadeny-
lated mRNA using an SP6 RNA-polymerase kit (Ambion, Austin, TX).
Expression and helper mRNAs were then co-transfected in a 1:1 molar
ratio by electroporation into BHK cells, which were cultured for 24 h to
allow virion production. Supernatants containing virions were col-
lected, centrifuged at 2000  g for 10 min at 4 °C, and stored in liquid
nitrogen in 1-ml aliquots. Viral titers were evaluated by transducing
BHK cells and assessing GFP expression 18 h later by flow cytometry.
Only viral preparations capable of inducing GFP expression in more
then 50% of BHK cells at a 1:3000 dilution of viral supernatant were
used for subsequent megakaryocyte experiments.
Characterization of GFP-tagged Proteins—GFP, GFP-Rap1b, and
GFP-Rap1GAP proteins were characterized by incubating NIH 3T3
cells with a 1:3 dilution of recombinant virus in 1% Dulbecco’s modified
Eagle’s medium/fetal calf serum for 1 h at 37 °C. After 10-fold dilution
in the same medium without virus, cells were cultured another 6 h, and
expression of recombinant proteins was assessed in Nonidet P-40 de-
tergent-solublized cell lysates by Western blotting (26). Blots were
probed with a monoclonal antibody to GFP (1:500 dilution; CLON-
TECH) and an horseradish peroxidase-conjugated anti-mouse IgG sec-
ondary antibody (1:3000 dilution; Bio-Rad Laboratories). Immunoreac-
tive bands were detected by enhanced chemiluminescence using
SuperSignal WestPico reagent (Pierce).
GTP loading of Rap1b was detected by a pull-down assay (14). NIH
3T3 cells were lysed at 4 °C in RIPA buffer containing 75 mM NaCl, 1%
Nonidet P-40, 1% deoxycholic acid, 0.2% sodium dodecyl sulfate, 2.5 mM
MgCl2, 1 mM sodium orthovanadate, 1 mM phenylmethylsulphonyl flu-
oride, 2 M leupeptin, 2 M aprotinin, and 50 mM Tris/HCl, pH 7.4. After
clarification, 500 g of protein in 500 l were incubated with 30 l of a
50% slurry of glutathione-Sepharose beads precoupled to either GST or
the GST-Rap binding domain of RalGDS. After three washes with RIPA
buffer, the presence of GFP or GFP-Rap1b proteins in the pellets, and
the amounts of recombinant or endogenous Rap1 in the starting mate-
rial were examined by Western blotting with an antibody to either GFP
or Rap1 (Santa Cruz Biotechnology, Santa Cruz, CA).
Transduction of GFP-tagged Proteins into Megakaryocytes—Bone
marrow cells were harvested from 6 to 8-week-old BALB/c mice and
cultured in the presence of thrombopoietin, IL-6, and IL-11 as described
(26). After 5 days, mature, polyploid megakaryocytes were enriched by
gravity sedimentation for 60 min at 37° in a 50-ml conical polypropylene
tube and then applied to a discontinuous density gradient of 1–2-3%
bovine serum albumin in phosphate-buffered saline, pH 7.4. After grav-
ity sedimentation for 30 min at 37°, cells were resuspended in complete
Iscove’s Modified Dulbecco’s medium to 2  105/ml, and 0.5-ml aliquots
were added to 100-mm dishes previously blocked with 1% bovine serum
albumin in phosphate-buffered saline. Cells were infected with 2 ml of
a 1:1 dilution of recombinant Sindbis virus for 1 h at 37° and then
diluted with 5 ml of complete medium and incubated for 6 h in a CO2
incubator.
Analysis of Fibrinogen Binding to Megakaryocytes—After viral infec-
tion, megakaryocytes were collected in 50-ml polypropylene tubes and
sedimented by gravity for 60 min at 37°. Cells were gently resuspended
in modified Tyrode’s buffer (137 mM NaCl, 2.9 mM KCl, 12 mM NaHCO3,
0.1 mM CaCl2, 0.1 mM MgCl2, 0.1% bovine serum albumin, 0.1% glucose,
5 mM HEPES, pH 7.4), and incubated for 20 min at room temperature
in a final volume of 50 l in the presence of 200 g/ml biotin-fibrinogen,
0.5 or 1 mM PAR4 thrombin receptor-activating peptide (AYPGFK) (27),
and 10 g/ml phycoerythrin-streptavidin (Molecular Probes, Eugene,
OR). To assess nonspecific binding, parallel samples were incubated
with either 10 mM EDTA or 20 g/ml 1B5, a function-blocking antibody
specific for murine IIb3 (a gift from Barry Coller, New York) (28). In
some cases, cells were pre-incubated for 10 min with either 10 M
cytochalasin D, latrunculin A or an equivalent volume of Me2SO vehicle
before addition of fibrinogen and agonist. Fibrinogen binding to large
megakaryocytes was quantified by flow cytometry (26). Surface expres-
sion of IIb3 was determined by flow cytometry after incubating cells
with 10 g/ml biotinylated anti-murine IIb antibody or an isotype-
matched control IgG (BD PharMingen, San Diego, CA).
Development of a Recombinant Antibody Fab Fragment Specific for
High Affinity Murine IIb3—PAC-1 Fab is a recombinant IgG1, RGD-
containing antibody Fab fragment specific for high affinity human
IIb3 (29). To determine whether Rap1b modulates IIb3 affinity in
mouse megakaryocytes, PAC-1 was re-engineered to recognize high
affinity murine IIb3. Specifically, PAC-1 Fab heavy chain cDNA was
subjected to splice-overlap extension PCR such that an 11-amino acid
stretch of H-CDR-3 (PSYYRGDGAGP) was replaced with a 13-amino
acid stretch from kistrin (CRIPRGDMPDDRC), an integrin-binding
snake venom peptide (30). When expressed as a secreted heavy chain
along with the PAC-1 light chain in Drosophila S2 cells (31), the
resulting Fab fragment, named POW-2, was found to be selective for
high affinity murine IIb3 (see “Results”). Serum-free S2 culture su-
pernatant containing POW-2 Fab was concentrated 10-fold and dia-
lyzed extensively against phosphate-buffered saline. Preliminary stud-
ies showed that the Fab in this preparation was monomeric by size
exclusion chromatography on a Sephadex G-200 column (29). Further-
more, forced oligomerization of IIb3 in a Chinese hamster ovary cell
model system did not promote POW-2 Fab binding, indicating that
POW-2 was not sensitive to changes in IIb3 avidity (3). POW-2 Fab
interaction with mouse platelets and megakaryocytes was analyzed by
flow cytometry (29). For platelets, POW-2 binding was assessed with a
secondary goat anti-mouse Ig (HL) antibody (Fab)2 conjugated with
Alexa-488 (31). For megakaryocytes, POW-2 was used to compete for
biotin-fibrinogen binding.
RESULTS
Expression of GFP-Rap1 Chimeric Proteins—The purpose of
this investigation was to determine the role of Rap1b in IIb3
function. Toward this end, RNA Sindbis virus vectors encoding
either GFP, constitutively active GFP-Rap1b (V12), dominant-
negative GFP-Rap1b (N17), or GFP-Rap1GAP were introduced
into murine megakaryocytes, and fibrinogen binding to IIb3
was examined. GFP was fused to the N termini of these con-
structs to facilitate flow cytometric identification of transduced
cells. Prior to megakaryocyte studies, recombinant protein ex-
pression was verified by transducing murine NIH 3T3 cells and
examining Western blots of cell lysates with an antibody to
GFP. In each case, a single immunoreactive band with the
appropriate electrophoretic mobility was observed (Fig. 1A). To
determine whether GFP-Rap1b (V12) was active in the sense
that it was loaded with GTP, lysates from virally infected cells
were incubated with glutathione-Sepharose beads coated with
the GST-Rap1 binding domain of RalGDS, a Rap1b effector
(20). GFP-Rap1b (V12) bound to these beads, whereas GFP-
Rap1b (N17) and GFP did not (Fig. 1B). Binding of GFP-Rap1b
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(V12) was specific because it failed to bind to beads coated with
GST (not shown). GFP-Rap1GAP was functional in that it
eliminated GTP-loading of endogenous Rap1 (Fig. 1C). On the
basis of these results, these viral vectors were used to introduce
the GFP-tagged chimeras into megakaryocytes.
Rap1b and Inside-out IIb3 Signaling in Megakaryocytes—
Large, mature megakaryocytes derived from bone marrow cul-
tures were incubated for 6 h with Sindbis viruses encoding the
GFP-tagged chimeras, and fibrinogen binding was then exam-
ined by flow cytometry (26). The light scattering mode of the
flow cytometer was used to identify large megakaryocytes, the
FL1 fluorescence channel to identify virally transduced, GFP-
positive cells, the FL2 channel to quantify the binding of biotin-
fibrinogen (using phycoerythrin-streptavidin), and the FL3
channel to exclude propidium iodide-positive, dead cells. After
viral infection, the percentage of large megakaryocytes that
expressed the recombinant GFP proteins ranged from 10 to
50% from experiment to experiment. Fig. 2 shows the fibrino-
gen binding data for a single experiment in the form of dot
plots, where cells expressing the recombinant protein are above
the horizontal lines and cells not expressing the recombinant
protein are below the horizontal lines. Note that megakaryo-
cytes that had been incubated with the control Sindbis virus
encoding GFP (Fig. 2, panels A and D) bound little or no
fibrinogen unless the cells were stimulated during the fibrino-
gen binding step with a PAR4 thrombin receptor-activating
peptide (AYPGKF) (27). Both GFP-positive and GFP-negative
cells appeared to respond in a similar fashion. Unstimulated
megakaryocytes expressing either GFP-Rap1b (V12), which is
constitutively active, or GFP-Rap1GAP, which inactivates en-
dogenous Rap1 (18), also bound little fibrinogen (Fig. 2, panels
B and C). In contrast, when stimulated with AYPGKF,
megakaryocytes expressing GFP-Rap1b (V12) appeared to bind
relatively more fibrinogen than non-expressing cells (Fig. 2,
panel E), while megakaryocytes expressing GFP-Rap1GAP ap-
peared to bind relatively less fibrinogen than non-expressing
cells (Fig. 2, panel F).
To validate the conclusions drawn from this single experi-
ment, the results of five such experiments are summarized in
Fig. 3, which depicts specific fibrinogen binding, defined as
binding inhibited by 10 mM EDTA. Neither GFP-Rap1b (V12)
nor GFP-Rap1GAP significantly influenced basal fibrinogen
binding to unstimulated megakaryocytes (Fig. 3A). However,
compared with megakaryocytes expressing GFP, those express-
ing GFP-Rap1b (V12) bound significantly more fibrinogen in
response to AYPGKF (p  0.01), whether a subsaturating (0.5
mM) or a saturating (1 mM) concentration of the agonist was
employed (Fig. 3A). Identical results were obtained if 20 g/ml
1B5, a function-blocking anti-IIb3 antibody, was used instead
of EDTA to determine specific fibrinogen binding (not shown).
In contrast to the results with GFP-Rap1b (V12), cells express-
ing GFP-Rap1GAP bound 46% less fibrinogen than GFP-ex-
pressing cells in response to 1 mM AYPGKF (p  0.01). These
effects of GFP-Rap1b (V12) or GFP-Rap1GAP were confined to
the subpopulation of megakaryocytes in each sample that had
been successfully transduced (compare Fig. 3, A versus B). In
addition, in three independent experiments, transduction of
megakaryocytes with GFP-Rap1b (N17), which acts in a dom-
inant-negative fashion by binding to some Rap1 GEFs (32),
inhibited fibrinogen binding induced by 1 mM AYPGKF by 27 
8% (p  0.05). Taken together, these results establish that
Rap1b promotes agonist-induced fibrinogen binding to IIb3,
and this effect is cell-autonomous.
The observed effects of Rap1b and Rap1GAP expression on
fibrinogen binding to megakaryocytes suggest that Rap1b mod-
ulates IIb3 affinity and/or avidity. However, similar results
might be obtained if Rap1b were to modify expression levels of
IIb3 or if Sindbis virus infection, per se, were to somehow
alter the responsiveness of the megakaryocytes to agonists.
Therefore these potential confounding variables were investi-
gated. The levels of IIb3 expressed on the surface of
megakaryocytes were measured with an antibody to the IIb
subunit. None of the Sindbis virus constructs affected IIb3
expression, either before or after stimulation with AYPGKF
(Fig. 4A). Furthermore, transduction of megakaryocytes with
Sindbis virus encoding GFP did not affect agonist-induced fi-
brinogen binding when the responses of GFP-positive cells
were compared with GFP-negative cells (Fig. 4B), or when cells
exposed to virus were compared with mock-transfected cells
(not shown). We conclude that Rap1b modulates fibrinogen
binding to IIb3 by an effect on integrin affinity and/or avidity.
Mechanistic Aspects of Rap1b Function in Inside-out Signal-
ing—To begin to investigate the mechanism by which Rap1b
modulates fibrinogen binding to megakaryocytes, we developed
a novel reagent capable of reporting on changes in the affinity
of murine IIb3. PAC-1 is a murine IgM monoclonal antibody
specific for activated human IIb3 (33). Because it is multim-
FIG. 1. Expression of GFP-Rap1 proteins in murine cells. As
described under “Experimental Procedures,” NIH 3T3 cells were incu-
bated for 6 h with Sindbis viruses encoding either GFP, GFP-Rap1b
(V12), GFP-Rap1b (N17), or GFP-Rap1GAP. In panel A, cells were lysed
in Nonidet P-40 buffer and subjected to sodium dodecyl sulfate-polyac-
rylamide gel electrophoresis and Western blotting using anti-GFP an-
tibody as a probe. In panel B, cells were incubated with viruses encod-
ing GFP, GFP-Rap1b (V12), or GFP-Rap1b (N17), lysed in RIPA buffer,
and then subjected to a pull-down assay using glutathione-Sepharose
beads coated with GST-Rap1 binding domain of RalGDS. After wash-
ing, GFP-tagged proteins retained on the beads (e.g. GTP-Rap1b) were
analyzed on a Western blot using an anti-GFP antibody. In parallel, the
amount of recombinant GFP proteins in 10 g of each cell lysate (e.g.
total GFP) was assessed using an antibody to GFP. In panel C, infection
of cells with viruses encoding GFP or GFP-Rap1GAP was carried out in
the presence of 10% fetal calf serum, the latter added to stimulate
endogenous Rap1. After cell lysis, GTP-Rap1 retained on the beads and
total Rap1 in 10 g of cell lysate were assessed by Western blotting
using an antibody to Rap1.
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eric, PAC-1 IgM is sensitive to changes in both IIb3 affinity
and avidity. In contrast, and as might be predicted, a recombi-
nant, monomeric, and monovalent Fab fragment of PAC-1 is
sensitive only to changes in IIb3 affinity (3, 29). Because
PAC-1 Fab is specific for human IIb3, we re-engineered it to
recognize high affinity murine IIb3. By removing an 11-
amino acid segment from the H-CDR3 of PAC-1 Fab and re-
placing it with a 13-amino acid RGD-containing segment from
the disintegrin, kistrin, a new recombinant Fab fragment
called POW-2 was created (Fig. 5A). Recombinant POW-2
bound to IIb3 on agonist-activated mouse (or human) plate-
lets. Binding was specific for high affinity IIb3 because min-
imal binding was observed to unstimulated platelets, to stim-
ulated platelets incubated with EDTA, kistrin or antibody 1B5
to block fibrinogen binding to IIb3 or to stimulated platelets
incubated with dibutyryl cyclic AMP to inhibit platelet activa-
tion (Fig. 5B). Although kistrin recognizes V3 and 51 in
addition to IIb3, POW-2 only recognized IIb3 in murine cells
(not shown).
Therefore, POW-2 Fab was used to compete with biotin-
fibrinogen for binding to AYPGKF-stimulated mouse
megakaryocytes, with the rationale that it would compete suc-
cessfully only for binding to high affinity IIb3. POW-2 Fab
was used at 130 g/ml, a concentration that in preliminary
studies inhibited the specific binding of 50 g/ml biotin-fibrin-
ogen to AYPGKF-stimulated mouse platelets by 95%. As
shown in Fig. 5C, POW-2 Fab inhibited agonist-dependent
fibrinogen binding to GFP-expressing megakaryocytes by 75%
and to GFP-Rap1b (V12)-expressing megakaryocytes by 82%.
In fact, POW-2 was almost as good a competitor of biotin-
fibrinogen as was an excess of unlabeled fibrinogen (Fig. 5C).
This substantial blockade of fibrinogen binding by POW-2 Fab
suggests that AYPGKF and Rap1b (V12) modulate the affinity
of IIb3.
Because IIb3 interacts with and may be regulated by com-
ponents of the platelet actin cytoskeleton (11, 34), we examined
whether inhibition of actin polymerization affected Rap1b (V12)-
dependent fibrinogen binding to stimulated megakaryocytes.
FIG. 2. Effect of Rap1b on fibrinogen binding to megakaryocytes. Megakaryocytes were incubated for 6 h with Sindbis viruses encoding
either GFP (panels A and D), GFP-Rap1b (V12) (panels B and E) or GFP-Rap1GAP (panels C and F). Cells were then incubated for 20 min with
200 g/ml biotin-fibrinogen in the presence or absence of 1 mM PAR4 receptor-activating peptide (AYPGKF), and fibrinogen binding was assessed
by flow cytometry using phycoerythrin-strepavidin as the fluorophore. Each panel is a dot plot representing 10,000 large megakaryocytes. Blue dots
below the horizontal lines represent cells not expressing the recombinant protein, and red dots above the horizontal lines are cells expressing the
protein. The number in each dot plot represents the percentage of all GFP-positive events present in the upper right hand quadrant.
FIG. 3. Effect of Rap1b on specific fibrinogen binding to megakaryocytes. Data for five independent experiments of the kind illustrated
in the legend to Fig. 2 are summarized. Specific fibrinogen binding was defined as that inhibited by 10 mM EDTA. It was expressed relative to the
binding observed with agonist-stimulated megakaryocytes incubated with the Sindbis/GFP virus, which was arbitrarily set at 100%. Data are the
means  S.E. Asterisks represent significant differences from the GFP sample, determined by Student’s t test (p  0.01).
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Pre-incubation of GFP-expressing megakaryocytes with 10 M
cytochalasin D blocked fibrinogen binding induced by AYPGKF
by 40%, consistent with previous studies of this concentration
of cytochalasins in platelets (11, 35, 36). More importantly,
cytochalasin D completely blocked the increment in fibrinogen
binding caused by GFP-Rap1b (V12) (Fig. 6). Similar results
were obtained if actin polymerization was blocked with 10 M
latrunculin A instead of cytochalasin D (not shown). Thus,
Rap1b may regulate IIb3 affinity and fibrinogen binding
through effects on the actin cytoskeleton.
DISCUSSION
In this study, recombinant human Rap1b constructs were
expressed in primary murine megakaryocytes to assess the
potential role of this GTPase in inside-out IIb3 signaling.
Megakaryocytes were chosen because they respond to platelet
agonists by engaging fibrinogen via IIb3, but unlike their
anucleate platelet progeny, they are amenable to genetic ma-
FIG. 4. Effect of Sindbis virus infection on IIb3 expression
and function in megakaryocytes. In panel A, megakaryocytes were
incubated for 6 h with the indicated Sindbis viruses, and surface ex-
pression of IIb3 was determined by flow cytometry, using an antibody
specific for the IIb subunit. Where indicated, cells were stimulated with
1 mM PAR4 receptor-activating peptide (AYPGKF) during the binding
assay. Data are presented as specific binding of the anti-IIb antibody
and expressed relative to the binding observed with unstimulated,
non-transduced (GFP-negative) megakaryocytes that had been incu-
bated with the Sindbis/GFP virus. In panel B, megakaryocytes were
incubated with Sindbis virus encoding GFP. Biotin-fibrinogen binding
was then assessed in the presence or absence of AYPGKF and 10 mM
EDTA, as indicated. Binding is expressed as mean fluorescence inten-
sity in arbitrary units. Data represent the means  S.E. of 3–7
experiments.
FIG. 5. Characterization of POW-2 Fab and its effect on fibrin-
ogen binding to megakaryocytes. Panel A shows the amino acid
sequences within the H-CDR3 regions of PAC-1 and POW-2 Fabs. The
bold letters represent the swapped sequences that converted PAC-1 Fab
into POW-2 Fab. Panel B validates the binding specificity of POW-2 Fab
for IIb3 using murine platelets and flow cytometry, as described under
“Experimental Procedures.” Incubation of platelets with 130 g/ml
POW-2 Fab was carried out for 30 min in the presence of an agonist and
inhibitors, as indicated. The agonist was 1 mM AYPGKF, EDTA was
used at 10 mM, kistrin at 5 M, 1B5 at 20 g/ml, and dibutyryl cyclic
AMP (db-cAMP) at 1 mM. Panel C shows the effect of 130 g/ml POW-2
Fab on the specific binding of 50 g/ml biotin-fibrinogen to megakaryo-
cytes. Where indicated, 0.5 mg/ml of unlabeled fibrinogen was used
instead of POW-2 Fab as a competitor. Data represent the means  S.E.
of three experiments.
FIG. 6. Effect of cytochalasin D on specific fibrinogen binding
to megakaryocytes. Megakaryocytes were transduced with Sindbis/
GFP or Sindbis/GFP-Rap1b (V12) viruses. Cells were then incubated for
10 min with 10 M cytochalasin D (CD) or Me2SO vehicle as a control,
and fibrinogen binding was determined by flow cytometry. The data
represent specific fibrinogen binding to transduced megakaryocytes
and is expressed relative to binding observed with agonist-stimulated
cells transduced with the Sindbis/GFP virus. Data are the means  S.E.
of three experiments.
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nipulation (25, 26, 37). The major new findings are the follow-
ing. 1) Expression of constitutively active Rap1b (V12) aug-
ments fibrinogen binding to IIb3 when megakaryocytes are
stimulated through the PAR4 thrombin receptor. In contrast,
expression of Rap1GAP, which inactivates endogenous Rap1,
or expression of Rap1b (N17), a dominant-negative construct,
has the opposite effect. 2) Modulation of fibrinogen binding by
Rap1b appears to be due primarily to effects on IIb3 affinity.
3) Regulation of IIb3 activation state by Rap1b may depend
on the actin cytoskeleton, because no Rap1b effect was ob-
served if actin polymerization was blocked by cytochalasin D or
latrunculin A. These results establish a role for Rap1b in af-
finity modulation of IIb3, and they raise important new ques-
tions about the identities and mechanisms of action of the
relevant Rap1b regulators and effectors in megakaryocytes and
platelets.
GFP-Rap1b and GFP-Rap1GAP constructs were introduced
into mature, bone marrow-derived mouse megakaryocytes us-
ing Sindbis viruses. In this system, the recombinant proteins
were expressed rapidly, and cell integrity was preserved long
enough for functional studies of IIb3 to be carried out. Indeed,
viral transduction, per se, had no detrimental effect on IIb3
surface expression or on agonist-induced fibrinogen binding
(Fig. 4). In addition, N-terminal fusion of GFP to these con-
structs did not adversely affect their function, as exemplified by
the ability of Rap1b (V12) to bind GTP and the ability of
GFP-Rap1GAP to reduce GTP loading of endogenous Rap1
(Fig. 1). Because expression of GFP alone did not interfere with
agonist-induced fibrinogen binding to megakaryocytes, the op-
posing effects on fibrinogen binding of GFP-Rap1b (V12) and
GFP-Rap1GAP provide strong evidence that IIb3 activation
can be modulated by Rap1b (Figs. 2 and 3). Furthermore,
although the recombinant proteins used here were human in
origin, the high degree of sequence conservation between hu-
man and murine Rap1b (e.g. 85% overall amino acid identity;
95% in the switch regions)2 indicates that our results are un-
likely to be complicated by species differences.
One caveat in overexpression work with Rap1b (V12) and
Rap1b (N17) is that the results obtained may not necessarily
reflect the function of endogenous Rap1b. For example, domi-
nant-negative Rap1b (N17) may exert functions in addition to
the expected one of titrating Rap1 GEFs, and it may not titrate
all Rap1 GEFs (32). Indeed, this may explain why GFP-
Rap1GAP was a better inhibitor of agonist-induced fibrinogen
binding to megakaryocytes than GFP-Rap1b (N17) (e.g. 46%
versus 27%). Nonetheless, the present study demonstrates un-
ambiguously that Rap1b can promote inside-out signaling to
IIb3 in primary megakaryocytes, thus providing a strong
rationale to further evaluate the functional relationships be-
tween Rap1b and IIb3 in platelets. The rapid activation of
Rap1b in platelets stimulated with thrombin, ADP, or epineph-
rine is consistent with a role in inside-out signaling (14–17).
Rap1b is a substrate for protein kinase A in platelets (38).
While the significance of phosphorylation to Rap1b function is
unclear, the phosphorylation of one or more proteins by protein
kinase A inhibits agonist-induced ligand-binding to IIb3 in
platelets (39). Perhaps Rap1b is one of the relevant protein
kinase A substrates in this context.
This work provides new insights into the role of Rap1b in
integrin function. Previous studies in fibroblasts, various he-
matopoietic cell lines and murine thymocytes have demon-
strated that overexpression of Rap1 or its GEFs and GAPs
affects cell adhesion, aggregation, and phagocytosis dependent
on 1 or 2 integrins (18–22, 40). Because all of these responses
involve integrin ligation as well as post-ligand binding events,
these observed effects of Rap1 do not necessarily pinpoint
which phase is targeted by the GTPase. However, in one study
employing a B lymphocyte cell line, Rap1 (V12) increased the
expression of an activation epitope on L2 and the binding of
a soluble ICAM-1/IgG fusion protein to the cells, consistent
with affinity modulation of L2 by Rap1 (19). On the other
hand, work in transgenic thymocytes concluded that Rap1 was
sufficient to modulate the clustering and avidity, rather than
the affinity, of 1 and 2 integrins (22).
In megakaryocytes, Rap1b increased fibrinogen binding to
IIb3, but only when the cells were stimulated with an agonist
(Figs. 2 and 3). This suggests that signals from Rap1b are not
sufficient to activate IIb3, but rather they may be required to
achieve maximal IIb3 activation in response to agonist-trig-
gered signals. Furthermore, the results with POW-2, a mono-
meric and monovalent ligand-mimetic Fab specific for high
affinity murine IIb3, establish that Rap1b functions, in large
part, by modulating IIb3 affinity in megakaryocytes (Fig. 5).
Overall, these results indicate that Rap1 is capable of regulat-
ing the activation state of 1, 2, and 3 integrins. However, the
precise mechanism of regulation, e.g. affinity versus avidity
modulation, appears to depend on the integrin and the cell
type. Future studies should consider the possibility that Rap1
may also influence post-ligand binding events, such as changes
in cell shape or polarity (13).
How is Rap1b activated in megakaryocytes and platelets,
and which Rap1b effector(s) modulate IIb3 affinity? Address-
ing these questions is made complicated by the plethora of
Rap1 GEFs and GAPs in various cells and tissues, some of
which are not specific for Rap1 (13, 41–43). Furthermore, the
effector functions of many of the known proteins that bind
selectively to GTP-Rap1 have yet to be completely character-
ized (13, 44). Most importantly, relatively little information is
available about the repertoire of Rap1 regulators and effectors
in platelets and megakaryocytes. Because Rap1b (V12) aug-
mented the fibrinogen binding response to a PAR4 thrombin
receptor agonist, the relevant Rap1 GEFs or GAPs may them-
selves be regulated by signaling molecules activated down-
stream of one or more heterotrimeric G proteins. In this con-
text, the products of phospholipase C-mediated phospholipid
hydrolysis, Ca2 and diacylglycerol, have been implicated in
agonist-dependent Rap1b activation in platelets (17). Indeed,
platelets and megakaryocytes contain a Rap1 GEF (CalDAG-
GEFI) likely to be activated by Ca2 and diacylglycerol (41,
45).3 Potential Rap1 effectors identified in platelets include
RalGDS, p110 PI 3-kinase, and Raf-1 (13, 46–48).
Integrins are coupled to actin filaments through actin-bind-
ing proteins, such as -actinin, filamin, and talin (12). Conse-
quently, a conceptual link is often made between changes in the
actin cytoskeleton and changes in integrin clustering or avidity
(4, 22, 49). We found that inhibition of actin polymerization by
10 M latrunculin A or cytochalasin D blocked Rap1b-depend-
ent fibrinogen binding to megakaryocytes (Fig. 6). Because
fibrinogen binding is controlled primarily by changes in IIb3
affinity (Fig. 5) (3), we propose that Rap1b may regulate IIb3
affinity through an effect on actin dynamics or organization. A
causal link between changes in actin and changes integrin
affinity has not been established unambiguously. However,
this idea is consistent with the recent observation that rela-
tively low concentrations of cytochalasin D or latrunculin A,
which may release integrins from cytoskeletal constraints, in-
crease agonist-dependent fibrinogen binding to platelets (11).
2 G. C. White, unpublished observations.
3 R. Murphy, K. Eto, S. Kerrigan, A. Bertoni, S. Shattil, and A.
Leavitt, unpublished observations.
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In this regard, at least two Rap1b effectors in platelets, Ral-
GDS and p110 PI 3-kinase, have been proposed to influence
actin filament organization (46, 47, 50). Studies in cell lines
have demonstrated that Ras family members in addition to
Rap1, such as H-Ras and R-Ras, can influence ligand binding to
integrins, although the net effects vary considerably among cell
types (51–53). Given the suitability of primary megakaryocytes
for the molecular analysis of IIb3 signaling, the experimental
system employed here should prove useful for identifying the
physiological regulators and effectors of Rap1b responsible for
modulating IIb3 affinity and for determining the roles of
other Ras family members in IIb3 function.
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